(Bloomberg) -- Samsung Biologics Co. will buy 49.9% of Samsung Bioepis from Biogen Inc., according to a regulatory filing, giving the South Korean drugmaker full ownership of the joint venture. Most Read from BloombergApple to Rival Square by Turning iPhones Into Payment TerminalsStocks Drop in Roller-Coaster Ride for Wall Street: Markets WrapCrypto Secrecy Makes DeFi a Financial Felon’s WonderlandHow a Fox News Interview Threw the Antiwork Subreddit Into ChaosAmericans’ Gas Stoves Are as Bad fo
The companies will continue with their exclusive agreements, including for commercialization of their current portfolioCAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to USD $2.3 billion.Biogen and Samsung Bioepis have built the industry leading anti-TNF portfolio in Europe1.
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.